Remove 2027 Remove Documentation Remove Drug Development
article thumbnail

Wearables, Sensors, and Apps Part 1 – Updates on FDA’s PDUFA VII Goals for the Use of Digital Health Technologies in Drug and Biological Product Development

FDA Law Blog: Biosimilars

This blog provides an update on the DHT-related PDUFA VII goals that were targeted for completion in the first two quarters of FDA’s Fiscal Year (FY) 2023, including: By the end of Q2 FY 2023, FDA will establish a DHT framework document to guide the use of DHT-derived data in regulatory decision-makings for drugs and biological products.

article thumbnail

Pre-Filled Syringes East Coast 2022

pharmaphorum

million in 2020 and with the rapid growth of the industry, is expected to grow at a CAGR of 8.95% up to 2027. Smart device developers. Training device developers. Drug developers. Understand requirements to facilitate the documentation preparation needed to obtain a NB Opinion. Medical Device Engineers.

article thumbnail

NHC Comments on IRA Guidance Response

Putting Patients First Blog

Driven by the work of the Food and Drug Administration on patient-focused drug development (PFDD), many companies in the biopharmaceutical community have devoted significant resources to better understand patient populations and are working to bring to market products that best suit their needs. Sincerely, Randall L.